Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

RT @DrMiguelPerales: #ASH15 #MSK Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies https://t.co/oUC9PAISZ9

Our data indicate that CD99 is expressed in a subset of T-lineage neoplasms. While there is no evidence for a functional role of CD99 in the growth or survival of T-ALL and ALCL, CD99 can be targeted by CD99 mAbs to induce apoptosis with rapid kinetics and in a manner that is dependent on levels of CD99 expression and independent of complement. Thus, CD99 is a promising target in the treatment of a subset of T-cell neoplasms.

Sourced through Scoop.it from: ash.confex.com

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY